West Pharmaceutical Services Salute del bilancio
Salute finanziaria criteri di controllo 6/6
West Pharmaceutical Services ha un patrimonio netto totale di $2.8B e un debito totale di $202.6M, che porta il suo rapporto debito/patrimonio netto a 7.4%. Le sue attività totali e le sue passività totali sono rispettivamente $3.7B e $923.0M. L'EBIT di West Pharmaceutical Services è $594.1M rendendo il suo rapporto di copertura degli interessi -30.9. Ha liquidità e investimenti a breve termine pari a $490.9M.
Informazioni chiave
7.4%
Rapporto debito/patrimonio netto
US$202.60m
Debito
| Indice di copertura degli interessi | -30.9x |
| Contanti | US$490.90m |
| Patrimonio netto | US$2.75b |
| Totale passività | US$923.00m |
| Totale attività | US$3.68b |
Aggiornamenti recenti sulla salute finanziaria
We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31Recent updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $1.6B ) di WST superano le sue passività a breve termine ( $516.5M ).
Passività a lungo termine: Le attività a breve termine di WST ( $1.6B ) superano le sue passività a lungo termine ( $406.5M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: WST ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di WST si è ridotto da 13.1% a 7.4% negli ultimi 5 anni.
Copertura del debito: Il debito di WST è ben coperto dal flusso di cassa operativo ( 346.7% ).
Copertura degli interessi: WST matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.